Neurological manifestations of antiphospholipid antibody syndrome

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Thrombosis, thrombocytopenia, recurrent fetal loss and a variety of non-thrombotic neurological disorders have all been associated with antiphospholipid antibodies (aPL). Cerebral ischemia associated with aPL is the most common arterial thrombotic manifestation. Depression, cognitive dysfunction, depression and psychosis have all been associated with aPL. The presumed pathophysiologic mechanism underlying these manifestations is thought to be a result of cerebral ischemia in some, but not all cases. Seizures, chorea and transverse myelitis all appear to be associated with aPL. An interaction between aPL and central nervous system cellular elements rather than aPL-associated thrombosis seems to be a more plausible mechanism for these clinical manifestations. Migraine on the other hand, does not appear to be associated with aPL in either lupus or non-lupus populations. Neuroimaging studies show an increased frequency of brain abnormalities in patients with aPL, bur none appear to be specific. The best treatment strategy for preventing neurological manifestations of aPL is not fully defined. For thrombotic manifestations, both antiplatelet and anticoagulant therapies have been suggested. In some patients, immunosuppressant therapy has been used. For non-thrombotic manifestations, some combination of immunosuppressant therapy and symptomatic treatment may be warranted.

Original languageEnglish (US)
JournalLupus
Volume7
Issue numberSUPPL. 2
StatePublished - 1998

Fingerprint

Antiphospholipid Antibodies
Antiphospholipid Syndrome
Neurologic Manifestations
Immunosuppressive Agents
Brain Ischemia
Thrombosis
Transverse Myelitis
Depression
Therapeutics
Chorea
Nervous System Diseases
Migraine Disorders
Neuroimaging
Thrombocytopenia
Psychotic Disorders
Anticoagulants
Seizures
Central Nervous System

Keywords

  • Anti-β-glycoprotein 1
  • Anticardiolipin antibody
  • Antiphospholipid syndrome
  • Chorea
  • Lupus anticoagulant
  • Migraine
  • Seizures
  • Stroke
  • Thrombosis
  • Transverse myelitis
  • Treatment

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Neurological manifestations of antiphospholipid antibody syndrome. / Brey, Robin L; Escalante, Agustin.

In: Lupus, Vol. 7, No. SUPPL. 2, 1998.

Research output: Contribution to journalArticle

@article{b92c1d7fefab405d81fd503790911f0f,
title = "Neurological manifestations of antiphospholipid antibody syndrome",
abstract = "Thrombosis, thrombocytopenia, recurrent fetal loss and a variety of non-thrombotic neurological disorders have all been associated with antiphospholipid antibodies (aPL). Cerebral ischemia associated with aPL is the most common arterial thrombotic manifestation. Depression, cognitive dysfunction, depression and psychosis have all been associated with aPL. The presumed pathophysiologic mechanism underlying these manifestations is thought to be a result of cerebral ischemia in some, but not all cases. Seizures, chorea and transverse myelitis all appear to be associated with aPL. An interaction between aPL and central nervous system cellular elements rather than aPL-associated thrombosis seems to be a more plausible mechanism for these clinical manifestations. Migraine on the other hand, does not appear to be associated with aPL in either lupus or non-lupus populations. Neuroimaging studies show an increased frequency of brain abnormalities in patients with aPL, bur none appear to be specific. The best treatment strategy for preventing neurological manifestations of aPL is not fully defined. For thrombotic manifestations, both antiplatelet and anticoagulant therapies have been suggested. In some patients, immunosuppressant therapy has been used. For non-thrombotic manifestations, some combination of immunosuppressant therapy and symptomatic treatment may be warranted.",
keywords = "Anti-β-glycoprotein 1, Anticardiolipin antibody, Antiphospholipid syndrome, Chorea, Lupus anticoagulant, Migraine, Seizures, Stroke, Thrombosis, Transverse myelitis, Treatment",
author = "Brey, {Robin L} and Agustin Escalante",
year = "1998",
language = "English (US)",
volume = "7",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Neurological manifestations of antiphospholipid antibody syndrome

AU - Brey, Robin L

AU - Escalante, Agustin

PY - 1998

Y1 - 1998

N2 - Thrombosis, thrombocytopenia, recurrent fetal loss and a variety of non-thrombotic neurological disorders have all been associated with antiphospholipid antibodies (aPL). Cerebral ischemia associated with aPL is the most common arterial thrombotic manifestation. Depression, cognitive dysfunction, depression and psychosis have all been associated with aPL. The presumed pathophysiologic mechanism underlying these manifestations is thought to be a result of cerebral ischemia in some, but not all cases. Seizures, chorea and transverse myelitis all appear to be associated with aPL. An interaction between aPL and central nervous system cellular elements rather than aPL-associated thrombosis seems to be a more plausible mechanism for these clinical manifestations. Migraine on the other hand, does not appear to be associated with aPL in either lupus or non-lupus populations. Neuroimaging studies show an increased frequency of brain abnormalities in patients with aPL, bur none appear to be specific. The best treatment strategy for preventing neurological manifestations of aPL is not fully defined. For thrombotic manifestations, both antiplatelet and anticoagulant therapies have been suggested. In some patients, immunosuppressant therapy has been used. For non-thrombotic manifestations, some combination of immunosuppressant therapy and symptomatic treatment may be warranted.

AB - Thrombosis, thrombocytopenia, recurrent fetal loss and a variety of non-thrombotic neurological disorders have all been associated with antiphospholipid antibodies (aPL). Cerebral ischemia associated with aPL is the most common arterial thrombotic manifestation. Depression, cognitive dysfunction, depression and psychosis have all been associated with aPL. The presumed pathophysiologic mechanism underlying these manifestations is thought to be a result of cerebral ischemia in some, but not all cases. Seizures, chorea and transverse myelitis all appear to be associated with aPL. An interaction between aPL and central nervous system cellular elements rather than aPL-associated thrombosis seems to be a more plausible mechanism for these clinical manifestations. Migraine on the other hand, does not appear to be associated with aPL in either lupus or non-lupus populations. Neuroimaging studies show an increased frequency of brain abnormalities in patients with aPL, bur none appear to be specific. The best treatment strategy for preventing neurological manifestations of aPL is not fully defined. For thrombotic manifestations, both antiplatelet and anticoagulant therapies have been suggested. In some patients, immunosuppressant therapy has been used. For non-thrombotic manifestations, some combination of immunosuppressant therapy and symptomatic treatment may be warranted.

KW - Anti-β-glycoprotein 1

KW - Anticardiolipin antibody

KW - Antiphospholipid syndrome

KW - Chorea

KW - Lupus anticoagulant

KW - Migraine

KW - Seizures

KW - Stroke

KW - Thrombosis

KW - Transverse myelitis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0031762245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031762245&partnerID=8YFLogxK

M3 - Article

C2 - 9814677

AN - SCOPUS:0031762245

VL - 7

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - SUPPL. 2

ER -